Случай острой стероид-индуцированной миопатии у пациентки с аутоиммунной тромбоцитопенией (клинический слу чай)

Статья посвящена одному из частых побочных эффектов терапии глюкокортикоидов — стероидной миопатии. Приводятся сведения о патогенетич еских особенностях развития миопатии при применении глюкокортикоидов, описываются наиболее типичные клинические проявления, а также результаты диагностических методов с оценкой роли измерения уровней ферментов, электромиографии, ультразвукового исследования мышечной ткани, компьютерной и магнитно-резонансной томографии. Приводится описание развития мышечной слабости у 49-летней больной, которой в связи с выявленной первичной иммунной тромбоцитопенией был назначен метилпреднизолон в суточной дозировке 88 мг. Через неделю терапии больная начала отмечать появление и нарастание мышечной слабости, ограничивающей движение и самообслуживание. После ряда выполненных исследований и, в частности, электромиографии, был предположен стероидный генез миопатии. После отмены глюкокортикоидов и назначения препаратов кальция, витамина D и анаболических средств, состояние больной стало улучшаться, и она была выписана из клиники.

тромбоцитопения, метилпреднизолон, глюкокортикоиды, побочные эффекты, стероидная миопатия, лечение

1. Cushing H. The basophil adenoma of the pituitary body and their clinical manifestation. J Neurosurg. 1932; 21(4): 318-47. doi: 10.3171/jns.1964.21.4.0318.

2. Pivonello R., Isidori A.M., De Martino M.C., et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016; 4(7): 611-29. doi: 10.1016/S2213-8587(16)00086-3.

3. Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013; 17(5): 913-6. doi: 10.4103/2230-8210.117215.

4. Owczarek .J, Jasińska M., Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005 ;57(1): 23-34. PMID: 15849374.

5. Schakman O, Kalista S., Barbé C., et al. Glucocorticoidinduced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013; 45(10): 2163-72. doi: 10.1016/j.biocel.2013.05.036.

6. Kostyo J.L., Redmond A.F. Role of protein synthesis in the inhibitory action of adrenal steroid hormones on amino acid transport by muscle. Endocrinology. 1966; 79(3): 531–40. doi: 10.1210/endo-79-3-531.

7. Liu Z., Li G., Kimball S.R., et al. Glucocorticoids modulate amino acid-induced translation initiation in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004; 287(2): E275–81. doi: 10.1152/ ajpendo.00457.

8. Hasselgren P.O. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care. 1999; 2(3): 201–5. doi: 10.1097/00075197199905000-00002.

9. Tiao G., Fagan J., Roegner V., et al. Energyubiquitindependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. JCI Insight. 1996; 97(2): 339–48. doi: 10.1172/JCI118421.

10. Bodine S.C., Latres E., Baumhueter S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547): 1704–8. doi: 10.1126/science.1065874.

11. Mitch W.E., Goldberg A.L. Mechanisms of muscle wasting. The role of the ubiquitinproteasome pathway. New Engl J Med. 1996; 335(25): 1897–905. doi: 10.1056/NEJM199612193352507.

12. Combaret L., Adegoke O.A., Bedard N., et al. USP19 is a ubiquitinspecific protease regulated in rat skeletal muscle during catabolic states. Am J Physiol Endocrinol Metab. 2005; 288(4): E693–700. doi: 10.1152/ajpendo.00281.2004.

13. Sacheck J.M., Ohtsuka A., McLary S.C., et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004; 287(4): E591–601. doi: 10.1152/ ajpendo.00073.2004.

14. Yamamoto D., Maki T., Herningtyas E.H., et al. Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve. 2010; 41(6): 819-27. doi: 10.1002/mus.21621.

15. Wang X.H., Zhang L., Mitch W.E., et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem. 2010; 285(28): 21249–57. doi: 10.1074/jbc.M109.041707.

16. Büyükcam F., Calık M., Erkuran M.K., et al. Hypokalemia and muscle paralysis after low-dose methylprednisolone. Am J Emerg Med. 2011; 29(5): 573.e1-2. doi: 10.1016/j.ajem.2010.05.00.

17. Fournier M., Huang Z.S., Li H., et al. Insulin-like growth factor-I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol. 2003; 285(1): R34–43. doi: 10.1152/ajpregu.00177.2002.

18. Shimizu N., Yoshikawa N., Ito N., et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metabolism. 2011; 13(2): 170–82. doi: 10.1016/j. cmet.2011.01.001.

19. Pereira R.M., Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011; 78(1): 41-4. doi: 10.1016/j. jbspin.2010.02.025

20. Полунина А.Г., Исаев Ф.В., Демьянова М.А. Стероидная миопатия (обзор). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012; 10(2): 60-64. PMID: 23250613.

21. Miller M.L. Glucocorticoid-induced myopathy. Indian J Endocrinol Metab. 2013; 17(5): 913-6. doi: 10.4103/2230-8210.117215.

22. Minetto M.A., Rainoldi A., Jabre J.F. The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies. J. Endocrinol. Invest. 2007; 30(9): 791-6. doi: 10.1007/BF03350820.

23. Minetto M.A., D’Angelo V., Arvat E., et al. Diagnostic work-up in steroid myopathy. Endocrine. 2018; 60(2): 219-23. doi: 10.1007/ s12020-017-1472-5.

24. Maffiuletti N.A. Assessment of hip and knee muscle function in orthopaedic practice and research. J. Bone Joint Surg. Am. 2010; 92(1): 220–9. doi: 10.2106/JBJS.I.00305.

25. Bohannon R.W. Measuring knee extensor muscle strength. Am. J. Phys. Med. Rehabil. 2001; 80(1): 13-8. doi: 10.1097/00002060200101000-00004.

26. Baudry S., Lanfranco F., Merletti R., et al. Effects of short-term dexamethasone administration on corticospinal excitability. Med. Sci. Sports Exerc. 2014; 46(4): 695–701. doi: 10.1249/ MSS.0000000000000162.

27. Khaleeli A.A., Edwards R.H., Gohil K., et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983; 18(2): 155-66. doi: 10.1111/j.1365-2265.1983.tb03198.

28. Lovitt S., Marden F.A., Gundogdu B., et al. MRI in myopathy. Neurol. Clin. 2004; 22(3): 509–538. doi: 10.1016/j. ncl.2004.03.008.

29. Zoico E., Corzato F., Bambace C., et al. Myosteatosis and myofibrosis: relationship with aging, inflammation and insulin resistance. Arch. Gerontol. Geriatr. 2013; 57(3): 411–6. doi: 10.1016/j.archger.2013.06.001.

30. Lee K., Shin Y., Huh J., et al. Recent issues on body composition imaging for sarcopenia evaluation. Korean J Radiol. 2019; 20(2): 205-17. doi: 10.3348/kjr.2018.0479.

31. Cartwright M.S., Demar S., Griffin L.P., et al. Validity and reliability of nerve and muscle ultrasound. Muscle Nerve. 2013; 47(4): 515–21. doi: 10.1002/mus.23621.

32. Arts I.M., Pillen S., Schelhaas H.J. , et al. Normal values for quantitative muscle ultrasonography in adults. Muscle Nerve. 2010; 41(1): 32-41. doi: 10.1002/mus.21458.

33. Atkinson R.A., Srinivas-Shankar U., Roberts S.A., et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J. Gerontol. A. Biol. Sci. Med. Sci. 2010; 65(11): 1215–9. doi: 10.1093/gerona/glq118.

34. Minetto M.A., Caresio C., Menapace T., et al. Ultrasound-based detection of low muscle mass for diagnosis of sarcopenia in older adults. PM&R. 2016; 8(5): 453–62. doi: 10.1016/j. pmrj.2015.09.014.

35. Minetto M.A., Caresio C., Salvi M., et al. Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing’s disease. J Endocrinol Invest. 2019; 42(7): 757-68. doi: 10.1007/s40618-018-0979-9.

36. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168-86. doi: 10.1182/ blood-2009-06-225565.

37. Witkowski M., Witkowska M., Robak T. Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. Eur J Haematol. 2019; 103(6): 531-41. doi: 10.1111/ejh.13319.

38. Khan M.A., Larson E. Acute myopathy secondary to oral steroid therapy in a 49-year-old man: a case report. J Med Case Reports. 2011; 5: 82. doi: 10.1186/1752-1947-5-82.

39. Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India. 2003; 51(4): 554-6. PMID: 14742950.

40. Haran M., Schattner A., Kozak N., et al. Acute steroid myopathy: a highly overlooked entity. QJM. 2018; 111(5): 307-11. doi: 10.1093/ qjmed/hcy031.

41. Liu Y., Chen S., Sun Y., et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. Medicine (Baltimore). 2016; 95(50): e5565. doi: 10.1097/MD.0000000000005565.

42. Buchman A.L. Side effects of corticosteroid therapy. J Clin Gastroenter ol. 2001; 33(4): 289-94. doi: 10.1097/00004836200110000-00006.